Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
47 hedge funds and large institutions have $161M invested in Omega Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 19 closing their positions.
10% less funds holding
Funds holding: 52 → 47 (-5)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
41% less capital invested
Capital invested by funds: $272M → $161M (-$110M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $157K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.61M |
| 2 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$1.17M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.04M |
| 4 |
Millennium Management
New York
|
+$752K |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$596K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$1.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.02M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$771K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$704K |
OMGA Hedge Fund Activity: Q2 2022 in Review
47 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q2 2022, worth a combined $161M — down 41% from $272M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of OMGA and 15 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 8 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.61M. The largest seller was BlackRock, cutting an estimated $4.5M.
- 47 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $161M of Omega Therapeutics, Inc. Common Stock stock for Q2 2022, down 41% quarter-over-quarter.
- 15 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q2 2022 and 19 closed out, a net change of -4 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q2 2022 was Laurion Capital Management, an estimated $1.61M added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2022.